Abstract Objectives: The UK Transcatheter Aortic Valve Implantation Registry reported 30-
day and 1-year mortality rates of 7.1% and 21.4%, respectively, for patients who underwent …

Objectives: The objective was to define the characteristics of a real-world patient population
treated with transcatheter aortic valve implantation (TAVI), regardless of technology or …

Transcatheter aortic valve implantation (TAVI) with the Cribier-Edwards prosthesis may
provide an alternative to conventional aortic valve replacement in high-risk patients with …

Background: Transcatheter aortic valve replacement (TAVR) has revolutionized
management of high-risk patients with severe aortic stenosis. However, survival and the …

Background In low surgical risk patients with symptomatic severe aortic stenosis, the
PARTNER 3 (Safety and Effectiveness of the SAPIEN 3 Transcatheter Heart Valve in Low …

Background Randomized data comparing outcomes of transcatheter aortic valve
replacement (TAVR) with surgery in low–surgical risk patients at time points beyond 2 years …

Importance In patients with severe aortic valve stenosis at intermediate surgical risk,
transcatheter aortic valve replacement (TAVR) with a self-expanding supra-annular valve …

Transcatheter aortic valve implantation (TAVI) is already an accepted option to treat elderly
patients with severe symptomatic aortic stenosis who are inoperable or at high surgical risk …

Introduction and objectives The treatment of severe symptomatic aortic stenosis has been
revolutionized by the technique of transcatheter valve replacement. The purpose of this …

Background Based on the early results of the Placement of Aortic Transcatheter Valves
(PARTNER) trial, transcatheter aortic valve replacement (TAVR) is an accepted treatment for …